Scarica l'app Stockscreener
152.67
1.40%
2.11
Dopo l'orario di chiusura:
152.86
0.19
+0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$150.56
Aprire:
$150.645
Volume 24 ore:
5.05M
Relative Volume:
0.74
Capitalizzazione di mercato:
$189.30B
Reddito:
$29.79B
Utile/perdita netta:
$9.22B
Rapporto P/E:
20.77
EPS:
7.3494
Flusso di cassa netto:
$10.23B
1 W Prestazione:
+4.35%
1M Prestazione:
+4.48%
6M Prestazione:
+11.27%
1 anno Prestazione:
+35.72%
Intervallo 1D:
$148.65
$153.28
Intervallo di 1 settimana:
$146.12
$153.28
Portata 52W:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
152.67 | 178.21B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,170.14 | 994.49B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
269.19 | 640.02B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.21 | 454.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.91 | 355.10B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.28 | 260.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-11 | Reiterato | Needham | Buy |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead Research Scholars Program in Solid Tumors 2026 - Oncodaily
Gilead Sciences, Inc. $GILD Stock Holdings Cut by Corient Private Wealth LP - MarketBeat
Sequoia Financial Advisors LLC Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
The Manufacturers Life Insurance Company Sells 148,344 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Bullseye Investment Management LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
RSU vesting leaves Gilead (NASDAQ: GILD) CMO with 270 new shares after tax - Stock Titan
Gilead Sciences stock gains support as HSBC lifts price target to USD 175 - ad-hoc-news.de
Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales - Yahoo Finance
Gilead Advances $32B U.S. Investment With New California Research Center - Business Facilities
Why is Gilead Sciences (NASDAQ:GILD) stock in focus today? - Kalkine Media
Gilead Sciences Share Price Today (GILD) | Live Chart, News & Stock Market - techgraph.co
Baird Financial Group Inc. Grows Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Key facts: Gilead Sciences, Inc. BIKTARVY ~52% U.S. HIV; HSBC PT $175 - TradingView
Gilead Sciences stock heads into the open after a 0.24% gain - ad-hoc-news.de
If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Gilead Sciences at 12th Annual Cantor Fitzgerald Global Healthcare Conference: broader growth - Investing.com Nigeria
GILD Maintained by HSBC -- Price Target Raised to $175 - GuruFocus
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth - MarketBeat
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
In draft guidance, NICE rebuffs Gilead's twice-a-year PrEP med for national coverage - Fierce Pharma
HSBC Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating - moomoo.com
Tidal Investments LLC Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by National Pension Service - MarketBeat
NICE says no to Gilead's lenacapavir for HIV PrEP - pharmaphorum
Gilead Sciences stock holds near highs as Q2 2026 EPS beats and new ex-dividend date nears - ad-hoc-news.de
Engineers Gate Manager LP Acquires Shares of 112,886 Gilead Sciences, Inc. $GILD - MarketBeat
Allworth Financial LP Sells 8,687 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences stock heads into the open after a 0.7 percent dip - ad-hoc-news.de
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode - MarketBeat
Gilead Sciences stock falls as investors reassess post-earnings rally - ad-hoc-news.de
Gilead launches research facility in US for new medicine development - Yahoo Finance
NewEdge Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
How Bixlenvo Approval At Gilead Sciences (GILD) Has Changed Its Investment Story - simplywall.st
Gilead opens new building on existing Foster City campus - NBC Bay Area
Gilead National Ribbon Cutting Ceremony - Post Register
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com South Africa
Assembly Bio stock gains after exercising Gilead profit option - Investing.com India
Gilead Sciences, Inc. (GILD) Stock Analysis: Evaluating the Prospects with a 4.25% Potential Upside - DirectorsTalk Interviews
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program - The Manila Times
A $75 million Gilead payment is due in Q4, while Assembly Bio expects cash to fund operations into 2029. - Stock Titan
Gilead Opens 182,000-Square-Foot Research Center in Foster City - Contract Pharma
Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement - TradingKey
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines - Gilead Sciences
Gilead Sciences stock gains on fresh analyst buy rating and Q2 loss swing - AD HOC NEWS
Gilead Sciences Slides 3.4% as Investors Digest Prior Gains and Ongoing Pricing Risks - Moomoo
Gilead opens research center as $32 billion US build-out continues - The Pharma Letter
Gilead Sciences, Inc. $GILD Shares Purchased by Groupe la Francaise - MarketBeat
California State Teachers Retirement System Has $30.47 Billion Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gilead Sciences Inc Azioni (GILD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Sep 15 '26 |
Sale |
144.22 |
3,000 |
432,646 |
116,684 |
1.01%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):